Back to journals
Academic JournalOpen Access

JAMA Network Open

12 Papers Indexed in Blossom

Data updated

Research Footprint

JAMA Network Open has 12 tracked papers indexed in Blossom (2023–2026) from 110 authors, most often covering Psilocybin, Placebo and Ketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Anxiety Disorders.

Published Papers

Open Accessmeta

Oral Prolonged-Release Ketamine for Treatment-Resistant Depression: Two Randomized Clinical Trials

This randomised clinical trial programme included a phase 1 crossover study (n=26) and a phase 2 placebo-controlled trial (n=122) testing oral prolonged-release ketamine for treatment-resistant depression. The oral tablet caused far less dissociation and cardiovascular change than intranasal esketamine, but it did not meet the main depression outcome at day 21, although some short-term symptom improvement was seen after the first dose.

Published
Journal
JAMA Network Open
Authors
Walter, M., zu Eulenburg, C., Damyanova, A., Schmid, K., Schwienbacher, I., Papanastasiou, E., Maiboe, K., Arvastson, L., Strote, C., Gehrlach, D., Eriksson, H.
Open Accessindividual

Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial.

This double-blind placebo-controlled randomised clinical trial (n=35) found that a single 25 mg dose of psilocybin, given with psychotherapy, reduced depression symptoms in people with moderate to severe recurrent major depressive disorder within days and for more than three months on some measures. Most side effects were mild or moderate, but two participants had severe anxiety that needed medical attention.

Published
Journal
JAMA Network Open
Authors
Yngwe, H., Plavén-Sigray, P., Ekman, C. J., Henje, E., Berglund, A., Tiger, M., Beckman, M., Lundberg, J.
Open Accessindividual

Psilocybin in the Treatment of Cocaine Use Disorder A Randomized Clinical Trial

This randomised quadruple-blind placebo-controlled clinical trial (n=40) found that a single 25 mg/70 kg dose of psilocybin, given with psychotherapy, increased cocaine-free days and delayed relapse compared with diphenhydramine in people with cocaine use disorder.

Published
Journal
JAMA Network Open
Authors
Hendricks, P. S., Lappan, S. N., Shelton, R. C., Lahti, A. C., Cropsey, K. L., Johnson, M. W., Bradley, M., Simonsson, O., Davis, L. L., Grossman, D. H., Ortiz, C. E.
Open Accessindividual

Psilocybin or Nicotine Patch for Smoking Cessation A Pilot Randomized Clinical Trial

This pilot randomised clinical trial (n=82) found that a single dose of psilocybin (30mg/70kg) combined with cognitive behavioural therapy produced significantly higher long-term smoking abstinence rates at 6 months compared to nicotine patches plus CBT (41% vs 10%), with no serious adverse events attributed to either treatment.

Published
Journal
JAMA Network Open
Authors
Johnson, M. W., Naudé, G. P., Hendricks, P. S., Garcia-Romeu, A.
Open Accessmeta

Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis

This meta-analysis of 17 trials found that control-group participants in psilocybin depression trials showed markedly smaller improvements (SMC ≈ 0.50) on the MADRS than control participants in SSRI (SMC ≈ 1.00) or esketamine (SMC ≈ 1.12) trials. The authors conclude this disparity may indicate that psilocybin’s antidepressant efficacy is overestimated relative to SSRIs and esketamine, possibly because of functional unblinding and expectancy effects.

Published
Journal
JAMA Network Open
Authors
Hieronymus, F., López, E., Sjögren, H. W., Lundberg, J.
Open Accessindividual

Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA: A Randomized Clinical Trial

In a double‑blind, placebo‑controlled within‑participant randomised trial of 16 adults stratified by baseline nonconscious‑threat–evoked amygdala activity, 120 mg MDMA acutely reduced amygdala and subgenual ACC activity, increased sgACC–amygdala connectivity, and raised likability of threat expressions in the high‑reactivity subgroup (NTNA+) versus the low‑reactivity subgroup. These results indicate that baseline neuroimaging of negative affect circuitry can identify biomarkers to personalise MDMA‑based therapies.

Published
Journal
JAMA Network Open
Authors
Zhang, X., Hack, L. M., Bertrand, C., Hilton, R., Gray, N. J., Boyar, L., Laudie, J., Heifets, B. D., Suppes, T., Van Roessel, P. J., Rodriguez, C. I., Deisseroth, K., Knutson, B., Williams, L. M.

Quick Facts

Papers Indexed
12
h-Index
154
Open Access
Yes
Publisher
American Medical Association
Country
United States
Website
Visit